Jacqueline Barrientos, MD, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data suggest that this may achieve minimum residual disease (MRD) negativity with a low risk of side effects.
Advertisement